Closely-held Ocutrx Vision Technologies appointed Dr. Linda Lam as chief scientific and strategy officer to guide new technology development, and help align current and future R&D efforts, industry trends and growth opportunities.
Dr. Lam is currently an associate professor of ophthalmology and vice chair of Satellite Clinical Affairs at the USC Keck School of Medicine.
Dr. Lam brings a deep expertise in complex medical and surgical vitreoretinal cases to Ocutrx. Her skill set also extends to clinical operations and strategy, research in macular degeneration, medical devices, and artificial intelligence research and vision rehabilitation.
In a statement, Michael Freeman, CEO and CTO of Ocutrx, said Dr. Lam’s commitment to innovation, scholarly research and improved patient outcomes is an excellent fit with Ocutrx’s flagship product, the Oculenz augmented reality glasses for low vision patients among other applications.
Dr. Lam said the work Ocutrx is doing to advance augmented reality products and broader medical technology in the augmented reality space is “revolutionary and broadly applicable across multiple demographics, industries and levels of visual impairments.”
